17 February 2016 - Praxbind (idarucizumab) is now available to be used commercially in England, Ireland and Wales after the Health Technology Appraisal bodies in these countries agreed that it is eligible for full reimbursment without the need for a full appraisal.

For more details, go to: http://www.businesswire.com/news/home/20160217005670/en/Praxbind®▼-idarucizumab-reimbursed-England-Ireland-Wales